Integrated Pharma Services

Executive Summary

Integrated Pharma Services (IPS) is a privately held, pre-clinical research organization founded in 2003 and headquartered in Horsham, Pennsylvania. IPS focuses on the development, evaluation, and advancement of novel antimicrobials and medical devices, operating as an award-winning research organization specializing in pre-clinical and clinical research. With a strong emphasis on combating antimicrobial resistance, IPS provides end-to-end services from discovery through early-stage clinical trials. Despite being in the pre-clinical stage, the company has established itself as a specialized partner for antimicrobial and medical device innovation, leveraging over two decades of experience. However, limited public information on funding, pipeline specifics, or partnerships suggests a low visibility profile. The company's success hinges on advancing its proprietary candidates through preclinical development and securing strategic collaborations or funding to enter clinical trials. Given the early stage and sparse data, the conviction in near-term value creation is moderate, with potential upside if key milestones are achieved.

Upcoming Catalysts (preview)

• Q3 2026Series A or Significant Funding Round35% success
• Q4 2026Announcement of First IND Filing for a Lead Antimicrobial Candidate20% success
• TBDStrategic Partnership with a Larger Pharma for Co-Development25% success